E-course: Update on adjuvant and neoadjuvant therapy for high-risk renal cancer
Examine the biological rationale, key clinical trials, and current guideline recommendations for the neoadjuvant and adjuvant treatment of renal cell carcinoma (RCC) in this e-coure organised by the European School of Urology and the EAU Section of Oncological Urology.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
The treatment of RCC is constantly advancing, with perioperative systemic therapies becoming an integral part of care for selected patients. Adjuvant immunotherapy has emerged as a standard option for high-risk disease following nephrectomy, while neoadjuvant strategies are being actively investigated to improve surgical outcomes and reduce the risk of recurrence.
This e-course will place particular emphasis on patient selection, biomarkers, multidisciplinary decision-making, and future directions that are likely to shape the next generation of perioperative RCC management.
Speakers:
- Prof. A. Volpe (IT)
- Dr. T. Kuusk (GB)
- Prof. Dr. J. Bedke (DE)
- Prof. A. Bex (GB)
This recording is brought to you in collaboration with the EAU Section of Oncological Urology.